

Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review

Mustafa Ghaderzadeh¹ , Armin Shalchian² , Gholamreza Irajian^{3,4} , Hamidreza Sadeghsalehi⁵
Abed Zahedi Bialvaei^{3*} , Babak Sabet^{6,7}

1. Boukan Faculty of Medical Sciences, Urmia University of Medical Sciences, Urmia, Iran
2. Department of Computer Engineering, Islamic Azad University, West Tehran Branch, Tehran, Iran
3. Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran
4. Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
5. Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
6. Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7. Department of Artificial Intelligence, Smart University of Medical Sciences, Tehran, Iran

ABSTRACT

Antimicrobial resistance (AMR) presents a formidable global health challenge, jeopardizing the efficacy of current antibiotics and posing a substantial threat to public health. The escalating prevalence of AMR demands innovative solutions. However, the traditional drug discovery process for combating AMR is marked by significant costs, prolonged timelines, frequent inefficacies, and numerous developmental hurdles. This narrative review explores the potential role of artificial intelligence (AI) in addressing AMR through drug discovery and development. It assesses the current state of AMR, critiques the limitations of conventional drug discovery methods, and elucidates the opportunities and advancements afforded by AI. The review delves into various AI applications, encompassing machine learning, deep learning, and language models, for the identification of novel antimicrobial agents, optimization of drug design, and prediction of AMR mechanisms. Additionally, it examines the integration of AI with high-throughput screening, genomics, and proteomics to expedite the discovery and development of new antimicrobial compounds. The review concludes by addressing challenges and ethical considerations linked to AI implementation in AMR research, emphasizing the imperative for collaborative efforts among scientists, policymakers, and healthcare professionals to effectively combat AMR.

Keywords: Artificial Intelligence, Drug Discovery, Drug Development, Antimicrobial Resistance, Machine Learning, Deep Learning

Received: 2024/04/27;

Accepted: 2024/07/17;

Published Online: 2024/08/18;

Corresponding Information:

Abed Zahedi Bialvaei, Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Email: zahedi.ab@iums.ac.ir



Copyright © 2024, This is an original open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits copy and redistribution of the material just in noncommercial usage with proper citation.



Use a device to scan and read the article online

Ghaderzadeh M, Shalchian A, Irajian G, Sadeghsalehi H, Zahedi bialvaei A, Sabet B. Artificial Intelligence in Drug Discovery and Development Against Antimicrobial Resistance: A Narrative Review. Iran J Med Microbiol. 2024;18(3):135-47.

Download citation: [BibTeX](#) | [RIS](#) | [EndNote](#) | [Medlars](#) | [ProCite](#) | [Reference Manager](#) | [RefWorks](#)

Send citation to: [Mendeley](#) [Zotero](#) [RefWorks](#)

1. Introduction

Antimicrobial resistance (AMR) poses a global health crisis wherein microorganisms like bacteria, viruses, fungi, and parasites develop resistance to antimicrobial drugs, diminishing their effectiveness in treating infections (1). This resistance jeopardizes the potency of antibiotics, antivirals, and antifungals, crucial for combating infectious diseases and

upholding public health. The proliferation of AMR carries profound consequences for healthcare systems on a global scale. The World Health Organization (WHO) reports that AMR leads to approximately 700,000 deaths annually, and if unchecked, this figure could escalate to 10 million deaths yearly by 2050, accompanied by a cumulative

economic burden of \$100 trillion (2). AMR not only increases the morbidity and mortality rates associated with infections but also contributes to prolonged hospital stays, increased healthcare costs, and reduced treatment options. It poses a particular risk to vulnerable populations, such as the elderly, newborns, and individuals with compromised immune systems (3, 4). The global impact of AMR extends beyond human health and affects veterinary medicine, agriculture, and food production due to the widespread use of antimicrobials in these sectors. AMR development and spread are fueled by the misuse and overuse of antimicrobials in humans and animals, coupled with inadequate infection prevention and control practices. Conventional drug discovery struggles to keep up with the rapid emergence of AMR, resulting in a limited pipeline of new antimicrobial agents. Therefore, addressing the multifaceted challenge of AMR requires a multidisciplinary approach and innovative strategies and technologies to ensure effective treatments for infectious diseases.

The need for innovative approaches in drug discovery arises from the scarcity of new antibiotics to combat the growing threat of AMR. The traditional drug discovery process, which relies on screening natural products and making chemical modifications, has fallen behind the rapid emergence of resistant bacteria. The high failure rates and long timelines associated with antibiotic development have discouraged pharmaceutical investment in this area (5).

Given this context, innovative approaches are essential to overcome AMR challenges and maintain a sustainable arsenal of effective antimicrobial agents. These approaches aim to identify new targets, develop novel compounds, and optimize existing antibiotics against resistant pathogens.

The integration of advanced technologies, such as artificial intelligence (AI), offers promising opportunities in drug discovery, surveillance, diagnostics, and personalized medicine.

This narrative review explores the integration of AI into drug discovery and development to combat antimicrobial resistance. It examines various AI applications in target identification, compound screening, lead optimization, and repurposing. The review also discusses the challenges and limitations associated with AI in AMR-focused drug discovery, as well as ethical considerations. By harnessing the potential of AI, it becomes possible to expedite the discovery of novel antimicrobial agents, optimize existing drugs, and effectively combat the growing threat of antimicrobial resistance.

1.1 Motivation

Several studies have extensively explored the applications of AI and machine learning (ML) in the analysis of data for drug discovery and development (6, 7). However, a noticeable gap exists in research concerning the utilization of AI in the specific domain of Antimicrobial Resistance, unlike the comprehensive studies in drug development. This gap in the literature has prompted the researchers of this manuscript to conduct a Narrative Review, filling the void and laying the groundwork for future studies in this crucial field. The aim is to contribute valuable insights to scientific communities and stimulate further exploration into the potential of AI in combating Antimicrobial Resistance.

1.2 AI Discipline and methods of AI

In recent years, there has been a significant rise in the digitalization of data within the pharmaceutical sector. However, this digital transformation poses challenges in terms of acquiring, analyzing, and effectively applying knowledge to address intricate clinical issues. This has led to a growing interest in the use of AI due to its ability to handle substantial amounts of data through improved automation. AI, as a technology-based system, incorporates various advanced tools and networks that emulate human intelligence without completely replacing human physical presence (8). AI employs systems and software capable of interpreting and learning from input data to autonomously make decisions in pursuit of specific objectives. The applications of AI in the pharmaceutical field are continually expanding, as discussed in this review. According to the McKinsey Global Institute, the swift progress in AI-guided automation is poised to bring about profound changes in societal work culture (9).

AI encompasses various methodological domains, including reasoning, knowledge representation, solution search, and, notably, a fundamental paradigm known as ML, Deep Learning (DL) and Language large models (Figure 1).

ML employs algorithms capable of identifying patterns within categorized datasets. Within ML, there exists a subfield known as deep learning, which employs artificial neural networks (ANNs) (10). These networks consist of interconnected sophisticated computing elements resembling human biological neurons, imitating the transmission of electrical impulses in the human brain. ANNs consist of nodes, each receiving distinct inputs and ultimately producing outputs, either individually or through multilinked configurations, utilizing algorithms to address problems (11). There are various types of ANNs, such as multilayer perceptron (MLP) networks,

2. Materials and Methods

The information obtained to write this study was collected from reliable databases including Scopus, PubMed and Google Scholar.

3. Results

In this investigation, we reviewed pertinent research in the scientific database, assessed the strengths and weaknesses of traditional approaches in drug development, categorized diverse artificial intelligence applications within the field of drug development, and conducted a thorough analysis of drug discovery methods, placing specific emphasis on addressing Antimicrobial Resistance.

3.1 Conventional Drug Discovery Approaches and Limitations

Conventional drug discovery approaches have played a vital role in the development of various antimicrobial agents. However, these approaches face several limitations, resulting in challenges in combating AMR. Phenotypic screening involves testing compounds for their ability to produce a desired biological effect in whole organisms or cells. This approach allows for the identification of compounds with desired activity but without the need for prior knowledge of the target. However, phenotypic screening often lacks mechanistic insights, making it challenging to optimize compounds or understand their specific mode of action (15). Additionally, the identification of the target can be laborious and time-consuming. On the other hand, target-based screening focuses on identifying compounds that interact with a specific target, such as a protein or enzyme involved in a disease pathway. This approach relies on knowledge of the target's structure and function. However, the identification of suitable targets can be difficult, particularly in complex diseases with poorly understood mechanisms (16). Moreover, the reliance on single targets may overlook the complexity of disease biology and the potential for compensatory mechanisms.

Combinatorial chemistry is another conventional drug discovery approach that involves the synthesis and screening of large libraries of compounds with diverse structures (17). This approach aims to explore a wide chemical space and identify compounds with desired biological activity. However, the sheer size of compound libraries makes screening and optimization challenging, as it requires significant time, resources, and expertise (18). Furthermore, combinatorial chemistry may not adequately explore the chemical diversity needed to address complex targets or pathways.

Natural products have served as a valuable source of drug leads. Extracts from plants, microbes, and marine

organisms have historically provided numerous bioactive compounds. However, the process of discovering and isolating natural products can be labor-intensive and time-consuming (19). Additionally, the limited supply and challenges in scaling up production have posed obstacles to their development as drugs. An essential aspect of drug discovery is ensuring that compounds have desirable pharmacokinetic properties, such as bioavailability, appropriate half-life, and metabolic stability. Furthermore, compounds must undergo rigorous safety assessments to determine their potential toxicity and side effects. These factors add to the complexity and cost of drug discovery, as compounds must meet stringent criteria for further development (20).

The challenges associated with traditional drug discovery methods have led to an increased interest in innovative approaches, such as AI, machine learning, and computational modeling, to overcome these limitations. By leveraging these technologies, researchers can analyze large datasets, model complex interactions, and design more efficient and targeted drug discovery strategies.

3.2 Crucial Role of AI in Tackling the AMR

AMR in bacteria is a global health crisis due to the rapid emergence of multidrug-resistant bacteria and the protracted development of new antimicrobials. The rise of AMR in bacteria since the 1940s has become a global health crisis (21). AMR develops through genetic mutation and spreads naturally through horizontal gene transfer. The long process of discovering and developing antimicrobials, including years of clinical trials, contrasts with the misuse and easy accessibility of antibiotics, leading to multidrug resistance (MDR) (22, 23). This crisis has resulted in a shortage of safe antimicrobials to combat MDR bacteria. To address this, rapid and efficient identification of bacterial AMR is crucial. AI, particularly ML, emerges as a novel approach for accurate and timely identification. ML involves training computers with large sets of experimental data. Databases like CARD and MegaRES collect peer-reviewed AMR determinants data, enabling the training of algorithms to reliably identify known or novel AMR and predict minimum inhibitory concentrations of MDR bacteria. This AI-based approach aims to combat the global AMR crisis and reduce antimicrobial misuse (24).

AI techniques have shown great potential in transforming various aspects of drug discovery and development. By leveraging large-scale genomic, proteomic, and metabolomic data, AI algorithms can aid in target identification, compound optimization, and prediction of antimicrobial resistance patterns (25, 26). These AI-driven approaches provide researchers with

valuable insights, enabling them to make informed decisions and prioritize resources effectively.

Furthermore, AI can facilitate the repurposing of existing drugs for antimicrobial use, allowing for a more rapid and cost-effective development process. Drug repurposing, combined with AI techniques, can help identify non-antibiotic compounds that possess antimicrobial activity, potentially expanding the repertoire of available treatments (27). This approach can offer a valuable alternative to traditional antibiotic development and overcome some of the challenges associated with de novo compound discovery.

The significance of innovative approaches in drug discovery extends beyond the development of new antimicrobial agents. It also encompasses the optimization of existing antibiotics to enhance their efficacy, minimize toxicity, and combat resistance mechanisms. AI-driven computational approaches, such as structure-based drug design and virtual screening, can facilitate the modification and optimization of antibiotic compounds, improving their pharmacological properties and reducing the likelihood of resistance development (28).

3.3 AI Applications in AMR

3.3.1 Traditional Machine learning in identifying antimicrobial compounds

Machine learning, a subset of artificial intelligence, has emerged as a powerful tool in drug discovery, including the identification of antimicrobial compounds. By leveraging large datasets, computational algorithms, and pattern recognition, machine learning techniques contribute to the rapid and efficient identification of potential antimicrobial agents. This section explores the role of machine learning in identifying antimicrobial compounds and provides relevant references supporting its application.

1. Data-driven Approaches: Machine learning algorithms can analyze vast amounts of data, including chemical structures, biological activity profiles, and genomic information, to identify patterns and relationships associated with antimicrobial activity. By learning from existing data, machine learning models can predict the antimicrobial potential of novel compounds and prioritize candidates for further experimental validation (26, 29).

2. Virtual Screening and Drug Repurposing: Machine learning techniques enable virtual screening, a computational approach used to identify potential antimicrobial compounds from large chemical libraries. By training models on known antimicrobial compounds and their properties, machine learning algorithms can efficiently screen millions of compounds and rank them according to their likelihood of exhibiting antimicrobial activity. Furthermore, machine learning can aid in drug

repurposing, identifying existing drugs with potential antimicrobial properties (30, 31).

3. Feature Extraction and Descriptors: Machine learning models require informative features or descriptors to capture the relevant characteristics of antimicrobial compounds. Various molecular descriptors, including physicochemical properties, molecular fingerprints, and structural fragments, can be used as input features for machine learning algorithms. These descriptors help in representing the compounds' chemical space and facilitate the prediction of their antimicrobial properties (32, 33).

4. Predictive Models and Optimization: Machine learning algorithms can build predictive models that classify compounds as antimicrobial or non-antimicrobial based on their features. These models can be trained on labeled datasets and optimized to improve their accuracy and generalizability. Additionally, machine learning can aid in optimizing the chemical structures of compounds to enhance their antimicrobial activity through virtual screening and molecular design (25, 34).

5. Antibiotic Resistance Prediction: Machine learning techniques can also be employed to predict and analyze antibiotic resistance. By analyzing genomic data from resistant strains, machine learning models can identify genetic markers and patterns associated with resistance mechanisms. This information can guide the development of novel antimicrobial compounds or strategies to combat resistance (35, 36).

3.3.2. Deep learning for drug design and optimization

Deep learning models can generate novel compounds with desired properties by learning patterns from large chemical databases. Generative models, such as generative adversarial networks (GANs) and variational autoencoders (VAEs), can produce structurally diverse compounds with specific chemical characteristics. These generated compounds can serve as starting points for further optimization and synthesis (37, 38).

Deep learning algorithms can accurately predict various molecular properties, such as solubility, bioactivity, toxicity, and binding affinity. By training on large datasets of chemical structures and their corresponding properties, deep learning models can learn complex relationships and make predictions on new compounds. These predictions aid in prioritizing compounds for synthesis and screening, thereby saving time and resources (39, 40). Deep learning models can also be employed for virtual screening, which involves computationally screening large compound libraries to identify potential hits against specific targets. CNNs and RNNs can analyze molecular structures, protein-ligand interactions, and binding affinities to rank compounds based on their likelihood of binding to a target. This

approach helps in identifying promising lead compounds for further experimental validation (41, 42).

Deep learning techniques enable de novo drug design, where the algorithm generates novel compounds with optimized properties. By incorporating desired molecular properties, constraints, and target interactions into the model, deep learning algorithms can explore the chemical space and propose compounds with improved efficacy and reduced off-target effects (43, 44). Additionally, deep learning algorithms can analyze large-scale biological and chemical data to identify new therapeutic indications for existing drugs. By integrating diverse datasets, such as gene expression profiles, drug-protein interactions, and disease networks, deep learning models can predict potential drug-disease associations and repurpose approved drugs for new indications (45, 46).

3.3.3 LLM in Drug discovery and development

Due to the novelty of this technology, its applications in the field of drug discovery and development have not been developed much. But this field has great potential in the development of new and recombinant drug structures. This interactive technology is able to provide constructive suggestions with the researchers of this field based on the topics that the model has learned on. LLM in Drug Discovery and Development can be a valuable tool in various aspects of the drug development process. But five accepted uses of an LLM can be listed and categorized by reviewing the research done (47, 48). A) Drug design and optimization: LLMs can generate new drug structures by inferring missing protein segments or small molecule sequences. These models can quickly generate new structures that can potentially be useful in drug development. B) Toxicity prediction: LLMs can be used to score new drug structures with respect to toxicity. By analyzing the generated structures, LLMs can provide insight into the potential toxicity of a drug candidate. C) Binding affinity prediction: LLMs can also predict the binding affinity of a drug candidate to its target protein. This information is very important in determining the effectiveness of a drug in interaction with its target and can help to optimize drugs. D) Ease of Synthesis Prediction: LLMs can assess the ease of synthesis of a drug candidate. This information is important in determining the feasibility and cost-effectiveness of large-scale production of a drug. E) Predicting pharmaceutical similarity: LLMs can evaluate the pharmaceutical similarity of a compound by considering various factors such as molecular weight, lipophilicity, and structural features. This evaluation helps identify compounds with a higher probability of success in drug development. It is noteworthy that while LLMs can generate new drug structures and provide predictions, further validation and experimental testing are necessary to confirm the efficacy and safety of these candidates.

3.3.4. Data mining and knowledge discovery in AMR databases

Data mining and knowledge discovery techniques play a crucial role in extracting valuable insights and patterns from large-scale AMR databases. By applying computational methods and statistical analysis to these databases, researchers can uncover hidden relationships, identify emerging resistance patterns, and guide the development of effective strategies to combat AMR. Data mining algorithms can identify patterns and clusters within AMR databases, enabling the discovery of novel resistance mechanisms and the characterization of resistance profiles. By analyzing large collections of microbial genomes and resistance phenotypes, clustering techniques, such as k-means clustering and hierarchical clustering, can group similar strains based on their resistance patterns and identify outliers with unique AMR characteristics (49, 50).

Association rule mining techniques, such as Apriori and FP-growth, can uncover associations and correlations between different antimicrobial resistance genes, mutations, and phenotypes. By analyzing AMR databases, these algorithms can identify co-occurring resistance genes or mutations, providing insights into the genetic determinants of resistance and potential gene interactions (51, 52). In addition, data mining approaches can build predictive models to forecast antimicrobial resistance based on various factors, including genomic data, patient demographics, and environmental conditions. Machine learning algorithms, such as decision trees, support vector machines (SVM), and random forests, can learn from historical data to predict the likelihood of resistance emergence or the effectiveness of specific antimicrobial treatments (53, 54). Network analysis techniques, such as graph theory and network clustering, can also reveal the complex relationships between AMR genes, mobile genetic elements, and bacterial strains. By constructing networks based on gene co-occurrence or genetic similarity, these methods can identify key resistance genes, transmission routes, and potential sources of resistance dissemination (55, 56).

Text mining and natural language processing techniques can extract valuable information from scientific literature, clinical reports, and other textual sources related to AMR. By analyzing and categorizing text data, these methods can identify novel resistance mechanisms, track the spread of specific resistance genes, and facilitate the curation and integration of AMR knowledge (57, 58).

3.3.5 Extra application of AI in combating AMR

3.3.5.1 AI in High-Throughput Screening, Genomics, and Proteomics

High-throughput screening (HTS), genomics, and proteomics are essential fields in drug discovery and biomedical research. The integration of AI into these fields has revolutionized the way scientists analyze and interpret large-scale biological data, leading to more efficient and accurate results. Research has demonstrated that AI has sparked innovation in various areas, including high-throughput screening, genomics, and proteomics.

3.3.5.2 Genomics analyzer equipped with AI

AI algorithms can analyze large-scale genomic data, including DNA sequencing and gene expression data, to identify patterns and associations that may be relevant to disease diagnosis, prognosis, and treatment. AI can help interpret genomic variants and help researchers identify disease-causing mutations and potential therapeutic targets. AI can predict gene functions and regulatory elements based on genomic data and help to understand gene networks and biological processes (59).

3.3.5.3 Proteomics Analyzer Equipped with AI

AI algorithms can analyze proteomics data, such as protein expression levels and post-translational modifications, to identify biomarkers for disease diagnosis, prognosis and treatment. AI can predict protein structures and interactions and help to understand protein function and drug-target interactions. AI can help identify potential drug targets by analyzing proteomics data and identifying proteins involved in disease pathways. Overall, the integration of AI into high-throughput screening, genomics, and proteomics has significantly increased the efficiency and accuracy of data analysis, leading to improved drug discovery findings and biomedical research outcomes (60).

3.3.5.4 Accelerating drug discovery through AI-powered screening

AI-powered screening methods leverage ML algorithms to analyze large datasets, predict compound properties, and prioritize molecules for further experimental validation. This section discusses the applications of AI-powered screening in drug discovery, supported by relevant references.

1. Virtual Screening: AI algorithms can perform virtual screening to computationally evaluate large libraries of compounds and identify potential drug candidates. Machine learning models, such as SVM, random forests, and deep learning architectures, can analyze molecular structures, physicochemical properties, and biological data to predict the likelihood of a compound's activity against a specific target. This approach helps in prioritizing compounds for experimental testing, reducing the time and cost associated with traditional screening methods (61, 62).

2. HTS Data Analysis: AI algorithms can analyze data generated from high-throughput screening campaigns, where thousands of compounds are tested against a target in a short period. By applying machine learning techniques, such as clustering, classification, and regression, to HTS data, AI models can identify active compounds, understand structure-activity relationships, and predict the potency of untested compounds. This enables researchers to make informed decisions and focus on the most promising molecules (26, 63).

3. De Novo Design: AI-powered approaches facilitate de novo drug design by generating novel compound structures with desired properties. Generative models, including generative adversarial networks (GANs) and variational autoencoders (VAEs), can learn from existing compound libraries and generate new molecules with optimized properties. By combining generative models with reinforcement learning techniques, AI algorithms can iteratively design and refine compounds based on target interactions and desired drug properties (38, 43).

4. Drug Repurposing: AI algorithms can mine large-scale biological and clinical datasets to identify potential new applications for existing drugs. By integrating diverse data sources, such as genomic data, electronic health records, and drug databases, AI models can predict novel drug-disease associations and repurpose approved drugs for new indications. This approach allows for the rapid identification of potential therapeutic options and reduces the time and cost required for preclinical and clinical development (64, 65).

5. Predictive ADME-Tox Modeling: AI techniques can predict the absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) properties of compounds. By training on large datasets of compound properties and experimental data, AI models can predict the pharmacokinetic and toxicological profiles of new compounds. This helps in identifying potential safety concerns and optimizing lead compounds early in the drug discovery process (66, 67).

3.3.5.5 Utilizing genomics and proteomics data for AMR prediction

Genomics and proteomics data provide valuable insights into the genetic and molecular mechanisms underlying AMR. By analyzing genomic sequences and proteomic profiles of microbial strains, researchers can identify genetic markers, resistance genes, and molecular pathways associated with AMR. Genomic data, including whole-genome sequencing (WGS) and metagenomic sequencing, can provide insights into the genetic basis of AMR (68). By comparing the genomic sequences of resistant and susceptible strains, researchers can identify genetic variations, mutations, and mobile genetic elements associated with resistance. Bioinformatics tools and machine learning algorithms can analyze these genomic features to predict the

likelihood of AMR and guide treatment decisions (69, 70).

The resistome refers to the collection of all resistance genes present in microbial genomes or metagenomic samples (71). HTS technologies enable researchers to profile the resistome and identify the repertoire of resistance genes within a microbial community. By analyzing the resistome, researchers can predict the potential resistance phenotypes and monitor the spread of resistance genes in various environments (72, 73). In addition, transcriptomic analysis, such as RNA sequencing (RNA-seq), can provide insights into the gene expression patterns associated with AMR. By comparing the transcriptomes of resistant and susceptible strains, researchers can identify differentially expressed genes and pathways involved in resistance mechanisms. This information can be used to predict AMR phenotypes and understand the regulatory networks underlying resistance (74, 75). Proteomics data can also contribute to AMR prediction by characterizing the protein expression profiles of resistant strains. Mass spectrometry-based proteomics enables the identification and quantification of proteins involved in resistance mechanisms. By comparing the proteomes of resistant and susceptible strains, researchers can identify differentially expressed proteins, post-translational modifications, and protein-protein interactions related to AMR (76, 77).

Integration of genomics, transcriptomics, proteomics, and other omics data can provide a comprehensive view of AMR mechanisms. By combining multiple layers of molecular information, researchers can identify key genetic variations, gene expression patterns, and protein interactions contributing to resistance. Integrated omics approaches, along with advanced data integration and machine learning techniques, can enhance AMR prediction and facilitate the development of personalized treatment strategies (78, 79).

3.3.5.6 AI-guided approaches for personalized medicine in AMR

AI plays a crucial role in advancing personalized medicine approaches for AMR. By leveraging AI algorithms, researchers can analyze diverse patient data, including genomics, clinical information, and microbial profiles, to develop tailored treatment strategies for individuals. AI algorithms can analyze genomic data, such as WGS or metagenomic sequencing, to identify genetic markers and resistance mechanisms associated with AMR. By integrating genomic information with clinical data, AI models can aid in precise diagnosis, determining the most effective antimicrobial treatment based on the patient's genetic profile (80, 81).

AI models can utilize machine learning techniques to analyze clinical and microbiological data to predict treatment outcomes for AMR infections. By

incorporating features such as patient demographics, comorbidities, antimicrobial resistance profiles, and treatment regimens, AI algorithms can help clinicians make informed decisions about the most suitable antibiotic therapy for individual patients (82, 83). AI-based models can analyze patient-specific data, including drug concentrations, pharmacokinetics, and clinical parameters, to optimize antimicrobial dosing through TDM. These models can help clinicians adjust dosages in real-time to ensure therapeutic efficacy while minimizing toxicity and the development of resistance (84, 85).

AI-powered decision support systems can integrate patient data, clinical guidelines, and expert knowledge to assist healthcare providers in selecting the most appropriate antimicrobial treatment (86). These systems can aid in decision-making by considering factors such as resistance patterns, individual patient characteristics, and local epidemiology (87). AI algorithms can also analyze large-scale, real-time data from electronic health records, laboratory records, and public health databases to detect AMR trends and outbreaks (88). By identifying patterns and anomalies, AI models can facilitate early detection, enabling timely intervention and the implementation of appropriate infection control measures (89).

5. Conclusion

The application of AI in combating AMR within drug discovery and development shows significant potential in addressing the global AMR challenge. This narrative review underscores the capabilities of AI across different phases of the drug discovery and development continuum, encompassing target identification, lead optimization, and the prediction of drug resistance. Various studies have validated the efficacy of AI-based approaches in identifying new antimicrobial compounds and enhancing existing drugs to combat AMR. Furthermore, AI demonstrates promise in forecasting drug resistance and guiding personalized treatment strategies. Despite notable advancements in this domain, there exist challenges and limitations that warrant attention. Additionally, ensuring the interpretability and explainability of AI models remains pivotal, particularly in the context of regulatory approval and clinical implementation.

Acknowledgment

We appreciate our colleagues in the Department of Microbiology of Iran University of Medical Sciences. In addition, we have a special thanks to Engr. Amirhossein Chehrehara who helped us in publishing this article.

Ethics approval

Not applicable.

Authors' Contributions

A.Z.B designed the study; M.G., A.S., A.Z.B. and H.S. collected data and prepared Manuscript draft; A.Z.B. and M.G. directed and managed the study; G.I. and B.S. revised critically and edited the manuscript. All authors studied and approved the final manuscript.

References

- Zahedi Bialvaei A, Eslami P, Ganji L, Dolatyar Dehkharghani A, Asgari F, Koupahi H, et al. Prevalence and epidemiological investigation of mgrB-dependent colistin resistance in extensively drug resistant *Klebsiella pneumoniae* in Iran. *Sci Rep.* 2023;13(1):10680. [PMCID] [DOI:10.1038/s41598-023-37845-z] [PMID]
- Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, et al. Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health. *Infect Drug Resist.* 2020;4:713-38. [DOI:10.2147/IDR.S290835] [PMID] [PMCID]
- World Health Organization (WHO). Antimicrobial resistance. 2023. Retrieved from: [https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance]
- O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016. London, UK: Wellcome Trust.
- Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. *Pharmaceuticals.* 2023;16(11):1615. [DOI:10.3390/ph16111615] [PMID] [PMCID]
- Esmailkhani A, Asadyun M, Nezamzadeh F, Keyvanfar E, Najafabadi N, Zahedi Bialvaei A. Establishing Artificial Intelligence and Reducing Health Care System Costs in Response to COVID-19. *Clin Lab.* 2022;68(5). [DOI:10.7754/Clin.Lab.2021.210848] [PMID]
- Shalchian A, Esmailkhani A, Razavi S. A review of the role of artificial intelligence in the diagnosis and treatment of infectious diseases. *Razi J Med Sci.* 2022;29(7):160-9.
- Fitria TN, Artificial intelligence (AI) in education: Using AI tools for teaching and learning process. *Proceeding Seminar Nasional & Call For Papers.* 2021;4(1):134-147.
- Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discovery*

Funding

The author(s) received no financial support for the research or publication of this article.

Conflict of Interest

No conflicts of interest were declared by the authors.

- Today. 2021;26(1):80. [PMCID] [DOI:10.1016/j.drudis.2020.10.010] [PMID]
- Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Campbell JP. Introduction to machine learning, neural networks, and deep learning. *Transl Vis Sci Technol.* 2020;9(2):14.
- Malik A, Lischuk Y, Henderson T, Prazenica R. Generating Constant Screw Axis Trajectories With Quintic Time Scaling For End-Effector Using Artificial Neural Network And Machine Learning. 2021 IEEE Conference on Control Technology and Applications (CCTA); 2021: IEEE. [DOI:10.1109/CCTA48906.2021.9658657]
- Abiodun OI, Jantan A, Omolara AE, Dada KV, Umar AM, Linus OU, et al. Comprehensive review of artificial neural network applications to pattern recognition. *IEEE Access.* 2019;7:158820-46. [DOI:10.1109/ACCESS.2019.2945545]
- Shang W, Huang X. A Survey of Large Language Models on Generative Graph Analytics: Query, Learning, and Applications. *arXiv preprint arXiv:240414809.* 2024.
- Yang J, Jin H, Tang R, Han X, Feng Q, Jiang H, et al. Harnessing the power of llms in practice: A survey on chatgpt and beyond. *ACM Trans Knowl Discov Data.* 2024;18(6):1-32. [DOI:10.1145/3649506]
- Swinney DC, Anthony J. How were new medicines discovered?. *Nat Rev Drug Discov.* 2011;10(7):507-19. [DOI:10.1038/nrd3480] [PMID]
- Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, et al. The promise and peril of chemical probes. *Nat Chem Biol.* 2015;11(8):536-41. [DOI:10.1038/nchembio.1867] [PMID] [PMCID]
- Liu R, Li X, Lam KS. Combinatorial chemistry in drug discovery. *Curr Opin Chem Biol.* 2017;38:117-26. [DOI:10.1016/j.cbpa.2017.03.017] [PMID] [PMCID]
- Wermuth U, Young D. Classics in Total Synthesis II: More Targets, Strategies, Methods. *Synthesis.* 2004;2004(05):809-. [DOI:10.1055/s-2004-822995]

19. Harvey A. Strategies for discovering drugs from previously unexplored natural products. *Drug Discovery Today*. 2000;5(7):294-300. [DOI:10.1016/S1359-6446(00)01511-7] [PMID]
20. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol*. 2011;162(6):1239-49. [PMID] [PMCID] [DOI:10.1111/j.1476-5381.2010.01127.x]
21. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. *Healthcare*. 2023;11(13):1946. [DOI:10.3390/healthcare11131946]
22. Esmailkhani A, Akhi MT, Sadeghi J, Niknafs B, Zahedi Bialvaei A, Farzadi L, et al. Assessing the prevalence of *Staphylococcus aureus* in infertile male patients in Tabriz, northwest Iran. *Int J Reprod Biomed*. 2018;16(7):469. [DOI:10.29252/ijrm.16.7.469] [PMID] [PMCID]
23. Zahedi Bialvaei A, Dolatyar Dehkharghani A, Asgari F, Shamloo F, Eslami P, Rahbar M. Modified CIM test as a useful tool to detect carbapenemase activity among extensively drug-resistant *Klebsiella pneumoniae*, *Escherichia coli* and *Acinetobacter baumannii*. *Ann Microbiol*. 2021;71(1):23. [DOI:10.1186/s13213-021-01634-8]
24. Lau HJ, Lim CH, Foo SC, Tan HS. The role of artificial intelligence in the battle against antimicrobial-resistant bacteria. *Curr Genet*. 2021;67(3):421-9. [PMID] [DOI:10.1007/s00294-021-01156-5]
25. Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. *Drug Discovery Today*. 2015;20(3):318-31. [DOI:10.1016/j.drudis.2014.10.012] [PMID]
26. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell*. 2020;180(4):688-702. e13. [PMCID] [DOI:10.1016/j.cell.2020.01.021] [PMID]
27. Fan Y-L, Jin X-H, Huang Z-P, Yu H-F, Zeng Z-G, Gao T, et al. Recent advances of imidazole-containing derivatives as anti-tubercular agents. *Eur J Med Chem*. 2018;150:347-65. [DOI:10.1016/j.ejmech.2018.03.016] [PMID]
28. Lluka T, Stokes JM. Antibiotic discovery in the artificial intelligence era. *Ann N Y Acad Sci*. 2023;1519(1):74-93. [PMID] [DOI:10.1111/nyas.14930]
29. Nayarisseri A, Khandelwal R, Tanwar P, Madhavi M, Sharma D, Thakur G, et al. Artificial intelligence, big data and machine learning approaches in precision medicine & drug discovery. *Curr Drug Targets*. 2021;22(6):631-55. [DOI:10.2174/1389450122999210104205732] [PMID]
30. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. *Pharmacol Rev*. 2014;66(1):334-95. [DOI:10.1124/pr.112.007336] [PMID] [PMCID]
31. Chew AK. *Molecular Dynamics and Machine Learning for Reaction and Nanomaterial Design*: The University of Wisconsin-Madison; 2021. 28492007.
32. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. *Chem Res Toxicol*. 2010;23(1):171-83. [DOI:10.1021/tx900326k] [PMID] [PMCID]
33. Lo Y-C, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. *Drug Discovery Today*. 2018;23(8):1538-46. [DOI:10.1016/j.drudis.2018.05.010] [PMID] [PMCID]
34. Sanchez-Lengeling B, Aspuru-Guzik A. Inverse molecular design using machine learning: Generative models for matter engineering. *Science*. 2018;361(6400):360-5. [DOI:10.1126/science.aat2663] [PMID]
35. Y Mahmood H, Jamshidi S, Mark Sutton J, M Rahman K. Current advances in developing inhibitors of bacterial multidrug efflux pumps. *Curr Med Chem*. 2016;23(10):1062-81. [DOI:10.2174/0929867323666160304150522] [PMID] [PMCID]
36. Weis CV, Jutzeler CR, Borgwardt K. Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review. *Clin Microbiol Infect*. 2020;26(10):1310-7. [DOI:10.1016/j.cmi.2020.03.014] [PMID]
37. Segler MH, Kogej T, Tyrchan C, Waller MP. Generating focused molecule libraries for drug discovery with recurrent neural networks. *ACS Cent Sci*. 2018;4(1):120-31. [PMID] [PMCID] [DOI:10.1021/acscentsci.7b00512]
38. Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, et al. Automatic chemical design using a data-driven continuous representation of molecules. *ACS Cent Sci*. 2018;4(2):268-76. [DOI:10.1021/acscentsci.7b00572] [PMID] [PMCID]
39. Unterthiner T, Mayr A, Klambauer G, Steijaert M, Wegner JK, Ceulemans H, et al. Deep learning as an opportunity in virtual screening. In *Proceedings of the deep learning workshop at NIPS*; 2014. Vol. 27, pp. 1-9. Cambridge, MA, United States: MIT Press.
40. Wallach I, Dzamba M, Heifets A. AtomNet: a deep convolutional neural network for

- bioactivity prediction in structure-based drug discovery. arXiv preprint arXiv:151002855. 2015.
41. Goh GB, Hodas NO, Vishnu A. Deep learning for computational chemistry. *J Comput Chem.* 2017; 38(16):1291-307. [DOI:10.1002/jcc.24764] [PMID]
 42. Liao Z, You R, Huang X, Yao X, Huang T, Zhu S. DeepDock: enhancing ligand-protein interaction prediction by a combination of ligand and structure information. 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM); 2019: IEEE. [DOI:10.1109/BIBM47256.2019.8983365]
 43. Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. *J Cheminform.* 2017; 9(1):1-14. [DOI:10.1186/s13321-017-0235-x] [PMID] [PMCID]
 44. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. *Sci Adv.* 2018;4(7):eaap7885. [DOI:10.1126/sciadv.aap7885] [PMID] [PMCID]
 45. Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, et al. Deep-learning-based drug-target interaction prediction. *J Proteome Res.* 2017;16(4):1401-9. [DOI:10.1021/acs.jproteome.6b00618] [PMID]
 46. Bai P, Miljković F, John B, Lu H. Interpretable bilinear attention network with domain adaptation improves drug-target prediction. *Nat Mach Intell.* 2023;5(2):126-36. [DOI:10.1038/s42256-022-00605-1]
 47. Guan S, Wang G. Drug discovery and development in the era of artificial intelligence: From machine learning to large language models. *Artif Intell Chem.* 2024;2(1):100070. [DOI:10.1016/j.aichem.2024.100070]
 48. Kathiriya S, Nuthakki S, Mulukuntla S, Charllo BV. AI and The Future of Medicine: Pioneering Drug Discovery with Language Models. *Int J Sci Res.* 2023;12(3):1824-9. [DOI:10.21275/SR24304173757]
 49. Han D, Gao P, Li R, Tan P, Xie J, Zhang R, et al. Multicenter assessment of microbial community profiling using 16S rRNA gene sequencing and shotgun metagenomic sequencing. *J Adv Res.* 2020;26:111-21. [PMID] [PMCID] [DOI:10.1016/j.jare.2020.07.010]
 50. Ruppé E, Ghozlane A, Tap J, Pons N, Alvarez A-S, Maziers N, et al. Prediction of the intestinal resistome by a three-dimensional structure-based method. *Nat Microbiol.* 2019;4(1):112-23. [DOI:10.1038/s41564-018-0292-6] [PMID]
 51. Razavi M, Kristiansson E, Flach C-F, Larsson DJ. The association between insertion sequences and antibiotic resistance genes. *Msphere.* 2020;5(5):e00418-20. [PMCID] [DOI:10.1128/mSphere.00418-20] [PMID]
 52. Torres MD, Cao J, Franco OL, Lu TK, de la Fuente-Nunez C. Synthetic biology and computer-based frameworks for antimicrobial peptide discovery. *ACS Nano.* 2021;15(2):2143-64. [PMCID] [DOI:10.1021/acsnano.0c09509] [PMID]
 53. Anahtar MN, Yang JH, Kanjilal S. Applications of machine learning to the problem of antimicrobial resistance: an emerging model for translational research. *J Clin Microbiol.* 2021;59(7): 10.1128/jcm.01260-20. [DOI:10.1128/JCM.01260-20] [PMID] [PMCID]
 54. Macesic N, Bear Don't Walk IV OJ, Pe'er I, Tatonetti NP, Peleg AY, Uhlemann A-C. Predicting phenotypic polymyxin resistance in *Klebsiella pneumoniae* through machine learning analysis of genomic data. *Msystems.* 2020;5(3): 10.1128/msystems.00656-19. [PMID] [PMCID] [DOI:10.1128/msystems.00656-19]
 55. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. *Clin Microbiol Rev.* 2018;31(4):10.1128/cmr.00088-17. [DOI:10.1128/CMR.00088-17] [PMID] [PMCID]
 56. Yu D, Ryu K, Zhi S, Otto SJ, Neumann NF. Naturalized *Escherichia coli* in Wastewater and the Co-evolution of Bacterial Resistance to Water Treatment and Antibiotics. *Front Microbiol.* 2022;13:810312. [PMID] [PMCID] [DOI:10.3389/fmicb.2022.810312]
 57. Smith NM, Boissonneault KR, Chen L, Petraitis V, Petraitiene R, Tao X, et al. Mechanistic Insights to Combating NDM-and CTX-M-Coproducing *Klebsiella pneumoniae* by Targeting Cell Wall Synthesis and Outer Membrane Integrity. *Antimicrob Agents Chemother.* 2022;66(9): e00527-22. [DOI:10.1128/aac.00527-22] [PMID] [PMCID]
 58. Magiorakos A-P, Suetens C, Monnet DL, Gagliotti C, Heuer OE, Group E-NC, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg?. *Antimicrob Resist Infect Control.* 2013;2:1-3. [DOI:10.1186/2047-2994-2-6] [PMID] [PMCID]
 59. Delgado FM, Gómez-Vela F. Computational methods for Gene Regulatory Networks reconstruction and analysis: A review. *Artif Intell Med.* 2019;95:133-45. [DOI:10.1016/j.artmed.2018.10.006] [PMID]
 60. Mann M, Kumar C, Zeng W-F, Strauss MT. Artificial intelligence for proteomics and biomarker discovery. *Cell Syst.* 2021;12(8):759-70. [DOI:10.1016/j.cels.2021.06.006] [PMID]
 61. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov.* 2019;18(6):463-77. [PMID] [DOI:10.1038/s41573-019-0024-5] [PMCID]

62. Dara S, Dhamecherla S, Jadav SS, Babu CM, Ahsan MJ. Machine learning in drug discovery: a review. *Artif Intell Rev.* 2022;55(3):1947-99. [DOI:10.1007/s10462-021-10058-4] [PMID] [PMCID]
63. Ramsundar B, Kearnes S, Riley P, Webster D, Konerding D, Pande V. Massively multitask networks for drug discovery. *arXiv preprint arXiv:150202072.* 2015.
64. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. *Mol Pharm.* 2016;13(7):2524-30. [PMID][PMCID] [DOI:10.1021/acs.molpharmaceut.6b00248]
65. Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. *Pharmacol Res.* 2017;124:74-91. [DOI:10.1016/j.phrs.2017.07.013] [PMID]
66. M Honorio K, L Moda T, D Andricopulo A. Pharmacokinetic properties and in silico ADME modeling in drug discovery. *Med Chem.* 2013; 9(2):163-76. [DOI:10.2174/1573406411309020002] [PMID]
67. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol.* 2019;37(9):1038-40. [DOI:10.1038/s41587-019-0224-x] [PMID]
68. Oniciuc EA, Likotrafiti E, Alvarez-Molina A, Prieto M, Santos JA, Alvarez-Ordóñez A. The present and future of whole genome sequencing (WGS) and whole metagenome sequencing (WMS) for surveillance of antimicrobial resistant microorganisms and antimicrobial resistance genes across the food chain. *Genes.* 2018;9(5): 268. [DOI:10.3390/genes9050268] [PMID] [PMCID]
69. Zankari E, Hasman H, Kaas RS, Seyfarth AM, Agersø Y, Lund O, et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. *J Antimicrob Chemother.* 2013;68(4):771-7. [DOI:10.1093/jac/dks496] [PMID]
70. Lakin SM, Dean C, Noyes NR, Dettenwanger A, Ross AS, Doster E, et al. MEGARes: an antimicrobial resistance database for high throughput sequencing. *Nucleic Acids Res.* 2017; 45(D1):D574-D80. [DOI:10.1093/nar/gkw1009] [PMID] [PMCID]
71. Bengtsson-Palme J, Larsson DJ, Kristiansson E. Using metagenomics to investigate human and environmental resistomes. *J Antimicrob Chemother.* 2017;72(10):2690-703. [DOI:10.1093/jac/dkx199] [PMID]
72. Forslund K, Sunagawa S, Kultima JR, Mende DR, Arumugam M, Typas A, et al. Country-specific antibiotic use practices impact the human gut resistome. *Genome Res.* 2013;23(7):1163-9. [DOI:10.1101/gr.155465.113] [PMID] [PMCID]
73. Hu Y, Yang X, Qin J, Lu N, Cheng G, Wu N, et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. *Nat Commun.* 2013;4(1):2151. [DOI:10.1038/ncomms3151] [PMID]
74. Westermann AJ, Förstner KU, Amman F, Barquist L, Chao Y, Schulte LN, et al. Dual RNA-seq unveils noncoding RNA functions in host-pathogen interactions. *Nature.* 2016;529(7587):496-501. [DOI:10.1038/nature16547] [PMID]
75. Chen L, Zhao X, Li R, Yang H. Integrated metabolomics and transcriptomics reveal the adaptive responses of *Salmonella enterica* serovar Typhimurium to thyme and cinnamon oils. *Food Res J.* 2022;157:111241. [DOI:10.1016/j.foodres.2022.111241] [PMID]
76. Malmström J, Beck M, Schmidt A, Lange V, Deutsch EW, Aebersold R. Proteome-wide cellular protein concentrations of the human pathogen *Leptospira interrogans*. *Nature.* 2009; 460(7256):762-5. [DOI:10.1038/nature08184] [PMID] [PMCID]
77. Pérez-Llarena FJ, Bou G. Proteomics as a tool for studying bacterial virulence and antimicrobial resistance. *Front Microbiol.* 2016;7:410. [PMID] [DOI:10.3389/fmicb.2016.00410] [PMCID]
78. Yamashita S, Hattori N, Fujii S, Yamaguchi T, Takahashi M, Hozumi Y, et al. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. *Sci Rep.* 2020;10(1):15530. [PMID] [PMCID] [DOI:10.1038/s41598-020-72661-9]
79. Chakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-multi-OMICS approach: a new frontier in cancer research. *Biomed Res Int.* 2018; 2018(1): 9836256. [DOI:10.1155/2018/9836256] [PMID] [PMCID]
80. Wang H, Jia C, Li H, Yin R, Chen J, Li Y, et al. Paving the way for precise diagnostics of antimicrobial resistant bacteria. *Front Mol Biosci.* 2022;9: 976705. [DOI:10.3389/fmolb.2022.976705] [PMID] [PMCID]
81. Tamma PD, Fan Y, Bergman Y, Perteza G, Kazmi AQ, Lewis S, et al. Applying rapid whole-genome sequencing to predict phenotypic antimicrobial susceptibility testing results among carbapenem-resistant *Klebsiella pneumoniae* clinical isolates. *Antimicrob Agents Chemother.* 2019;63(1): 10.1128/aac.01923-18. [DOI:10.1128/AAC.01923-18] [PMID] [PMCID]

82. Tacconelli E, Goepel S, Gladstone BP, Eisenbeis S, Hoelzl F, Buhl M, et al. Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study. *Lancet Infect Dis.* 2022;22(5):731-41. [PMID] [DOI:10.1016/S1473-3099(21)00587-9]
83. Nguyen M, Olson R, Shukla M, VanOeffelen M, Davis JJ. Predicting antimicrobial resistance using conserved genes. *PLoS Comput Biol.* 2020;16(10):e1008319. [PMID] [PMCID] [DOI:10.1371/journal.pcbi.1008319]
84. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β -lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy: J Hum Pharmacol Drug Ther.* 2006;26(9):1320-32. [DOI:10.1592/phco.26.9.1320] [PMID]
85. Avedissian SN, Rohani R, Bradley J, Le J, Rhodes NJ. Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: a convergence of parametric and nonparametric population approaches. *Antimicrob Agents Chemother.* 2021;65(4):10.1128/aac.02629-20. [DOI:10.1128/AAC.02629-20] [PMID] [PMCID]
86. Losier M, Ramsey TD, Wilby KJ, Black EK. A systematic review of antimicrobial stewardship interventions in the emergency department. *Ann Pharmacother.* 2017;51(9):774-90. [DOI:10.1177/1060028017709820] [PMID]
87. Rawson T, Moore L, Hernandez B, Charani E, Castro-Sanchez E, Herrero P, et al. A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?. *Clin Microbiol Infect.* 2017;23(8):524-32. [DOI:10.1016/j.cmi.2017.02.028] [PMID]
88. Rasheed J, Jamil A, Hameed AA, Al-Turjman F, Rasheed A. COVID-19 in the age of artificial intelligence: a comprehensive review. *Interdiscip Sci Comput Life Sci.* 2021;13:153-75. [PMCID] [DOI:10.1007/s12539-021-00431-w] [PMID]
89. Haeusler GM, Thursky KA, Mechinaud F, Babl FE, De Abreu Lourenco R, Slavin MA, et al. Predicting infectious complications in children with cancer: an external validation study. *Br J Cancer.* 2017;117(2):171-8. [DOI:10.1038/bjc.2017.154] [PMID] [PMCID]